Display options
Cite
Vanderpuye VDNK, Olopade OI, Huo D. Pilot Survey of Breast Cancer Management in Sub-Saharan Africa. J Glob Oncol. 2016;3(3):194-200doi: 10.1200/JGO.2016.004945.
Vanderpuye, V. D. N. K., Olopade, O. I., & Huo, D. (2017). Pilot Survey of Breast Cancer Management in Sub-Saharan Africa. Journal of global oncology, 3(3), 194-200. https://doi.org/10.1200/JGO.2016.004945
Vanderpuye, Verna D N K, et al. "Pilot Survey of Breast Cancer Management in Sub-Saharan Africa." Journal of global oncology vol. 3,3 (2017): 194-200. doi: https://doi.org/10.1200/JGO.2016.004945
Vanderpuye VDNK, Olopade OI, Huo D. Pilot Survey of Breast Cancer Management in Sub-Saharan Africa. J Glob Oncol. 2016 Dec 21;3(3):194-200. doi: 10.1200/JGO.2016.004945. eCollection 2017 Jun. PMID: 28717760; PMCID: PMC5493219.
Copy Download .nbib Format: NLM
Share it on

J Glob Oncol. 2016 Dec 21;3(3):194-200. doi: 10.1200/JGO.2016.004945. eCollection 2017 Jun.

Pilot Survey of Breast Cancer Management in Sub-Saharan Africa.

Journal of global oncology

Verna D N K Vanderpuye, Olufunmilayo I Olopade, Dezheng Huo

Affiliations

  1. , Korlebu Teaching Hospital, Accra, Ghana; and . Olopade and , University of Chicago, Chicago, IL.

PMID: 28717760 PMCID: PMC5493219 DOI: 10.1200/JGO.2016.004945

Abstract

PURPOSE: To understand the current state of breast cancer management in sub-Saharan Africa.

METHODS: We conducted an anonymous online survey of breast cancer management among African Organization for Research and Treatment in Cancer (AORTIC) members by using a 42-question structured questionnaire in both English and French in 2013.

RESULTS: Twenty members from 19 facilities in 14 countries responded to the survey. Twelve members (60%) belonged to a multidisciplinary breast cancer team. Radiotherapy equipment was available in seven facilities (36%), but equipment had down time at least once a week in four facilities. Available chemotherapy drugs included methotrexate, cyclophosphamide, fluorouracil, anthracyclines, and vincristine, whereas trastuzumab, taxanes, vinorelbine, and gemcitabine were available in few facilities. Core-needle biopsy was available in 16 facilities (84%); mammogram, in 17 facilities (89%); computed tomography scan, in 15 facilities (79%); magnetic resonance imaging, in 11 facilities (58%); and bone scans, in nine facilities (47%). It took an average of 1 to 3 weeks to report histopathology. Immunohistochemistry was available locally in eight facilities (42%), outside hospitals but within the country in seven facilities (37%), and outside the country in four facilities (21%). Thirteen facilities (68%) performed axillary node dissections as part of a breast protocol. Neoadjuvant chemotherapy was the most common therapy for locally advanced breast cancer in 13 facilities (68%). In three facilities (16%), receptor status did not influence the prescription of hormone treatment.

CONCLUSION: This pilot survey suggests that AORTIC members in sub-Saharan Africa continue to make gains in the provision of access to multidisciplinary breast cancer care, but the lack of adequate pathology and radiotherapy services is a barrier. Focused attention on in-country and regional training needs and improvement of health systems deliverables is urgently needed.

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Mem

References

  1. J Clin Oncol. 2001 Sep 15;19(18 Suppl):93S-97S - PubMed
  2. Saudi Med J. 2005 Jan;26(1):42-6 - PubMed
  3. N Engl J Med. 2006 Feb 23;354(8):809-20 - PubMed
  4. Acta Oncol. 2011 Apr;50(3):344-52 - PubMed
  5. Lancet Oncol. 2013 Apr;14(4):e168-75 - PubMed
  6. Oman Med J. 2013 Mar;28(2):125-7 - PubMed
  7. Lancet. 2013 Sep 21;382(9897):1021-8 - PubMed
  8. PLoS One. 2013 Aug 12;8(8):e71853 - PubMed
  9. Ann Oncol. 2013 Sep;24 Suppl 5:v13-6 - PubMed
  10. Yonago Acta Med. 2013 Jun;56(2):51-6 - PubMed
  11. Breast Cancer Res Treat. 2014 Apr;144(3):467-78 - PubMed
  12. CA Cancer J Clin. 2015 Mar;65(2):87-108 - PubMed
  13. PLoS One. 2015 Jun 26;10(6):e0131305 - PubMed
  14. Surgery. 2015 Sep;158(3):747-55 - PubMed
  15. Lancet Oncol. 2015 Sep;16(10):1153-86 - PubMed
  16. Lancet Oncol. 2015 Sep;16(11):1193-224 - PubMed
  17. J Glob Oncol. 2015 Sep 23;1(1):30-36 - PubMed
  18. J Glob Oncol. 2015 Oct 28;1(2):57-64 - PubMed

Publication Types